C M Bidwell & Associates LTD Abb Vie Inc. Transaction History

C M Bidwell & Associates LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$106.4 - $120.78 $115,763 - $131,408	-1,088 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$105.21 - $117.21 $2,630 - $2,930	25 Added 2.35%	1,088 $123,000
Q1 2021 May 14, 2021	BUY	$102.3 - $112.62 $4,194 - $4,617	41 Added 4.01%	1,063 $115,000
Q4 2020 Feb 16, 2021	SELL	$80.49 - $108.67 $19,398 - $26,189	-241 Reduced 19.08%	1,022 $110,000
Q3 2020 Nov 13, 2020	SELL	$85.91 - $100.83 $19,072 - $22,384	-222 Reduced 14.95%	1,263 $111,000
Q2 2020 Aug 14, 2020	SELL	$73.37 - $98.18 $2,934 - $3,927	-40 Reduced 2.62%	1,485 $146,000
Q1 2020 May 15, 2020	BUY	$64.5 - $97.79 $98,362 - $149,129	1,525 New	1,525 $116,000
Q3 2018 Nov 13, 2018	SELL	$88.91 - $98.84 $234,277 - $260,443	-2,635 Closed	0 $0
Q2 2018 Aug 13, 2018	SELL	$89.78 - $106.23 $226,694 - $268,230	-2,525 Reduced 48.93%	2,635 $244,000
Q1 2018 May 11, 2018	BUY	$92.01 - $123.21 $111,792 - $149,700	1,215 Added 30.8%	5,160 $488,000
Q4 2017 Feb 02, 2018	BUY	$89.56 - $98.21 $353,314 - $387,438	3,945	3,945 $382,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of C M Bidwell & Associates LTD, based on Form 13F filings with the SEC.

Stay updated on C M Bidwell & Associates LTD with notifications on news.